Cost-Effectiveness Studies in Oncology

[1]  Vinay Prasad,et al.  The high price of anticancer drugs: origins, implications, barriers, solutions , 2017, Nature Reviews Clinical Oncology.

[2]  Karl Claxton,et al.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.

[3]  P. Savage,et al.  Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014 , 2015, British Journal of Cancer.

[4]  C. Mullins,et al.  Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs? , 2014, Journal of managed care & specialty pharmacy.

[5]  Joshua T. Cohen,et al.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.

[6]  M. Buxton,et al.  Does Medicare Have an Implicit Cost-Effectiveness Threshold? , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  A. Bezjak,et al.  Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Stafford,et al.  Health state utilities for non small cell lung cancer , 2008, Health and quality of life outcomes.

[9]  D. Coyle,et al.  Cost-effectiveness analysis in oncology. , 1998, Praxis.

[10]  D. Provenzale,et al.  Cost-effectiveness: definitions and use in the gastroenterology literature. , 1996, The American journal of gastroenterology.

[11]  D. Coyle.  Statistical Analysis in Pharmacoeconomic Studies , 1996, PharmacoEconomics.

[12]  W. F. Van den Bogaert,et al.  Comparison of plastic and Orfit masks for patient head fixation during radiotherapy: precision and costs. , 1995, International journal of radiation oncology, biology, physics.

[13]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  D. Feeny,et al.  Utilities and Quality-Adjusted Life Years , 1989, International Journal of Technology Assessment in Health Care.

[15]  Michael Halpern,et al.  Association of Insurance with Cancer Care Utilization and Outcomes , 2008, CA: a cancer journal for clinicians.

[16]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.